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Red Cell Disorders
Impact of erythropoietic activity on red cell parameters in
chronic renal failure patients
We measured red cell parameters during recombinant
human erythropoietin (rHuEPO) therapy associated with
appropriate iron supplementation in chronic hemodialysis
patients. Increased erythropoietic activity led to a bias in
red cell parameter determination. The percentage of
hypochromic red blood cells, usually used as the most
effective predictor of response to iron suplementation,
increased following the appearance of a younger red cell
population since the same Hb content in these younger,
larger cells gives a lower Hb concentration.
haematologica 2004; 88:748-749
(http://www.haematologica.org/journal/2004/6/748)
The percentage of hypochromic red blood cells (%HYPO) is
the most sensitive and specific predictor of response to iron
supplementation when erythropoietin (rHuEPO) is adminis-
tered.1 However, we have previously shown that %HYPO is
positively influenced by the reticulocyte count.2 Initiation of
rHuEPO leads to reticulocytosis and the red blood cell (RBC)
population is renewed by younger cells. Both phenomenona
have been shown to increase %HYPO.3
In order to assess the influence of erythropoietic activity on
red cell parameters, we studied the evolution of RBC and
reticulocyte volume (MCV; MCVr), Hb content (MCH; MCHr),
Hb concentration (MCHC; MCHCr) and %HYPO from the ini-
tiation of rHuEPO in 6 chronic hemodialysis patients, free of
inflammation and transfusion. Erythropoietin was started
intravenously at the dose of 200 IU/kg/week in three doses
at the end of each dialysis session. To prevent iron deficien-
cy, 100 mg iron sucrose (Venofer®) was administered once
weekly from the start of rHuEPO therapy. Parameters were
determined weekly for 11 weeks following initiation of rHuE-
PO treatment. Table 1 shows the comparison of parameters
measured at the start and at the end of the follow-up. The Hb
level rose from 8.3±1.2 to 12.1±0.6 g/dL. Serum transferrin
receptors (sTfR) increased significantly (6.4±2.2 vs 3.4±1.5;
p=0.003). Despite intravenous iron supplementation, ferritin
(FRT) decreased by 50% (112.0±30.1 vs 214.2±130.5; p=NS)
whereas transferrin saturation (TSAT) only decreased from 18
to 15% (p=NS). Whereas CHr remained constant and within
the normal range, %HYPO was significantly higher at the end
of the follow-up (7.2±4.1 vs 1.7 ± 0.8 %; p<0.05). An increased
red cell volume (MCV) was observed (p<0.001), with a stable
Hb content (MCH). The same evolution was noted for the retic-
ulocyte parameters, i.e. a stable Hb content (MCHr), a non-sig-
nificant trend towards an increased volume (MCVr) and a low-
er Hb concentration (MCHCr) (p<0.05). Figure 1 depicts the
evolution of RBC and iron parameters over the whole period
of observation. The changes in MCV and MCHC predominant-
ly occurred during the first 4 weeks of rHuEPO therapy stabi-
lizing thereafter.
Table 1. Comparison of parameters measured at baseline
and the end of the follow-up.
Parameter Baseline Week 11 p
(m±sd) (m±sd) value
Hb (g/dL) 8.3±1.2 12.1±0.6 0.008
MCV (fL) 85.7±2.4 90.9±2.5 < 0.001
MCH (pg) 28.7±0.8 28.6± 1.8 0.89
MCHC (pg/mL) 33.7±0.6 32.3±0.5 0.14
%HYPO (%) 1.7±0.8 7.2±4.1 0.02
Retics (x1000/µL) 49.3±18.1 69.0±32.6 0.49
MCVr (fL) 107.8±2.5 112.3 ± 6.1 0.13
MCHr (pg) 32.4±0.7 31.8±2.1 0.56
MCHCr (pg/mL) 30.0±1.0 28.5±1.5 0.03
Ferritin (ng/mL) 214.2±130.5 112.0±30.1 0.13
TfSAT* (%) 18±3 15±3 0.20
sTfR°(mg/L) 3.4±1.5 6.6±2.2 0.003
*TfSAT: transferrin saturation; °sTfR:  serum transferrin receptors.
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The response to rHuEPO treatment is known to be depend-
ent on adequate iron supplementation.4,5 Intravenous iron
administration can be associated with acute and long-term
complications such as anaphylaxis, infection and oxidative
damage. To provide the best risk-benefit ratio, reliable pre-
dictors of response to iron supplementation are needed. The
%HYPO appears to fulfil this role1 but is also influenced by
both the reticulocyte count2,3 and a younger age of the RBC
population.3 The specificity and sensitivity of other markers
are not sufficient during rHuEPO therapy.6 Ferritin and trans-
ferrin saturation usually decrease during rHuEPO treatment.
However, these parameters have proven poor predictors of
response to iron supplementation.1 Discrepancies between
ferritin and TSAT are usual during rHuEPO treatment.7 sTfR
increased progressively during the study, but this parameter
is far more influenced by erythropoietic stimulation than by
iron deficiency8 With simultaneous administration of rHuE-
PO and iron, we observed that MCHr, an accurate early mark-
er of iron-deficient anemia,9,10 remained stable and normal,
whereas %HYPO increased progressively. This cannot be
explained by iron deficient erythropoiesis since MCHr and
MCH remained normal throughout the follow-up. In fact, the
explanation for this increase in %HYPO is a progressive
decrease of erythrocyte Hb concentration due to increasing
cell volume, mainly related to the appearance of a younger
red cell population, including reticulocytes. This phenomenon
was more important during the first 4 weeks of treatment
since peak reticulocytosis occurred 1 week after rHuEPO ini-
tiation and the ratio between young and older RBC decreas-
es as the anemia is corrected. A further increase in %HYPO
was observed at the end of the follow-up. As transferrin sat-
uration was below 20%, this could indicate a possible con-
tribution from functional iron deficiency.
Acute erythropoietic stimulation, induced by rHuEPO, leads
to reticulocytosis and renewal of the erythrocyte population
leading to biased determination of red cell Hb concentration
and percentage of hypochromic red blood cells. The specific
determination of RBC parameters of mature erythrocytes,
separately from those of reticulocytes, should provide a more
accurate assessment of functional iron deficiency under con-
ditions of increased erythropoietic activity.
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Chronic Myeloproliferative Disorders
Instability of PRV-1 mRNA: a factor to be considered in
PRV-1 quantification for the diagnosis of polycythemia
vera 
High expression of PRV-1 mRNA in granulocytes has been
proposed as a new diagnostic marker for polycythemia vera.
We used real-time reverse transcription polymerase chain
reaction (RT-PCR) to measure the levels of PRV-1 mRNA,
GAPDH mRNA and 18S rRNA in granulocytes obtained from
blood samples processed 2, 24 and 48 hours after collec-
tion and observed a significant decrease of PRV-1 levels
after 24 and 48 hours. The instability of PRV-1 mRNA may
affect the diagnostic value of the PRV-1 test in blood sam-
ples stored for extended periods. haematologica 2004; 88:749-751
(http://www.haematologica.org/journal/2004/6/749)
Polycythemia vera (PV) is the most common primary poly-
cythemia1 and is characterized by clonal expansion of myeloid
cells from an acquired mutation of a single stem cell. The
diagnosis of PV is based on the guidelines established by the
Polycythemia Vera Study Group,2 but atypical cases may not
be discriminated readily by these criteria. Recently, it has
been reported that levels of PRV-1 (polycythemia rubra vera-
1) mRNA are increased in PV granulocytes from peripheral
blood, but not in their progenitors.3-5 While some investiga-
tors report a clear distinction between elevated PRV-1 mRNA
in granulocytes of PV patients and low PRV-1 levels in nor-
mal controls,6 we and others have found overlaps between the
highest PRV-1 levels in healthy controls and the lowest lev-
els in PV patients.7-9 Further, the expression of PRV-1 mRNA
could be modulated by cytokines, i.e. upregulated by granu-
locyte colony-stimulating factor3 and downregulated by
interferon-α treatment.10 We hypothesized that PRV-1 mRNA
in granulocytes might also be less stable than the RNA species
used as internal references for PRV-1 quantification by real
time RT-PCR and here we report on PRV-1 mRNA instability.
We measured the levels of mRNA for PRV-1 in granulocytes
from 10 normal controls and 3 PV patients. The study was
approved by the Baylor College of Medicine (BCM) Istitu-
tional Review Board; all studied subjects participated in the
